BSE Live
Mar 19, 11:03Prev. Close
905.10
Open Price
890.05
Bid Price (Qty.)
904.55 (34)
Offer Price (Qty.)
907.15 (157)
NSE Live
Mar 19, 11:03Prev. Close
907.05
Open Price
895.00
Bid Price (Qty.)
905.25 (5)
Offer Price (Qty.)
905.70 (11)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 89.57 | 89.55 | 89.50 | 89.42 | 89.35 | |
| Total Share Capital | 89.57 | 89.55 | 89.50 | 89.42 | 89.35 | |
| Reserves and Surplus | 3,079.88 | 3,159.68 | 3,072.37 | 3,143.10 | 3,046.06 | |
| Total Reserves and Surplus | 3,079.88 | 3,159.68 | 3,072.37 | 3,143.10 | 3,046.06 | |
| Total Shareholders Funds | 3,175.17 | 3,256.80 | 3,161.87 | 3,232.53 | 3,135.41 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.15 | 2.45 | 769.45 | 880.70 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 33.62 | |
| Other Long Term Liabilities | 42.55 | 3.98 | 3.33 | 22.52 | 14.99 | |
| Long Term Provisions | 19.75 | 12.88 | 13.32 | 22.58 | 10.14 | |
| Total Non-Current Liabilities | 62.30 | 17.01 | 19.10 | 814.56 | 939.45 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 852.46 | 808.80 | 601.59 | 647.44 | 544.41 | |
| Trade Payables | 474.11 | 509.40 | 390.72 | 470.56 | 497.17 | |
| Other Current Liabilities | 92.44 | 49.49 | 84.90 | 290.28 | 195.69 | |
| Short Term Provisions | 18.78 | 21.31 | 26.84 | 25.87 | 51.87 | |
| Total Current Liabilities | 1,437.79 | 1,388.99 | 1,104.05 | 1,434.16 | 1,289.13 | |
| Total Capital And Liabilities | 4,675.25 | 4,662.80 | 4,285.16 | 5,481.24 | 5,363.99 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 493.52 | 444.59 | 432.51 | 837.87 | 781.73 | |
| Intangible Assets | 49.79 | 52.14 | 65.45 | 285.90 | 277.11 | |
| Capital Work-In-Progress | 86.03 | 72.56 | 86.89 | 99.63 | 126.42 | |
| Other Assets | 72.36 | 76.88 | 66.00 | 70.07 | 0.00 | |
| Fixed Assets | 724.48 | 696.07 | 707.81 | 1,351.58 | 1,238.92 | |
| Non-Current Investments | 2,170.57 | 1,994.59 | 1,465.19 | 1,240.70 | 1,233.92 | |
| Deferred Tax Assets [Net] | 81.04 | 80.12 | 53.51 | 19.34 | 0.00 | |
| Long Term Loans And Advances | 96.07 | 91.61 | 37.49 | 54.81 | 230.26 | |
| Other Non-Current Assets | 146.30 | 136.82 | 521.61 | 235.65 | 1.90 | |
| Total Non-Current Assets | 3,218.45 | 2,999.21 | 2,785.62 | 2,902.08 | 2,704.99 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 154.29 | 311.48 | 1,279.54 | 1,132.95 | |
| Inventories | 444.86 | 473.34 | 269.63 | 409.53 | 379.23 | |
| Trade Receivables | 661.46 | 582.56 | 449.37 | 540.69 | 702.30 | |
| Cash And Cash Equivalents | 108.43 | 180.81 | 79.79 | 94.92 | 94.34 | |
| Short Term Loans And Advances | 77.16 | 27.60 | 26.23 | 8.65 | 326.16 | |
| OtherCurrentAssets | 164.89 | 244.99 | 363.05 | 245.84 | 24.03 | |
| Total Current Assets | 1,456.80 | 1,663.59 | 1,499.54 | 2,579.16 | 2,659.01 | |
| Total Assets | 4,675.25 | 4,662.80 | 4,285.16 | 5,481.24 | 5,363.99 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 3,498.11 | 5,766.31 | 4,437.15 | 5,478.48 | 5,370.32 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 406.52 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 11.98 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 11.98 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 37.96 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 31.05 | 39.50 | 71.02 | 0.00 | 72.75 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | 0.04 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | 1,519.23 | |
| Other Earnings | 1,602.02 | 1,462.98 | 1,569.71 | -- | 141.95 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | -- | -- | 0.11 | 1,240.70 | 1,233.92 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | 154.29 | 311.48 | 1,279.54 | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | 1,132.95 |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth